EP0799893B1 - Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier - Google Patents

Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier Download PDF

Info

Publication number
EP0799893B1
EP0799893B1 EP97400796A EP97400796A EP0799893B1 EP 0799893 B1 EP0799893 B1 EP 0799893B1 EP 97400796 A EP97400796 A EP 97400796A EP 97400796 A EP97400796 A EP 97400796A EP 0799893 B1 EP0799893 B1 EP 0799893B1
Authority
EP
European Patent Office
Prior art keywords
plasmid
protein
plasmids
retroviral
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97400796A
Other languages
English (en)
French (fr)
Other versions
EP0799893A1 (de
Inventor
David Klatzmann
Jean-Loup Salzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Original Assignee
Universite Pierre et Marie Curie Paris 6
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie Paris 6 filed Critical Universite Pierre et Marie Curie Paris 6
Priority to EP01102630A priority Critical patent/EP1138773A2/de
Publication of EP0799893A1 publication Critical patent/EP0799893A1/de
Application granted granted Critical
Publication of EP0799893B1 publication Critical patent/EP0799893B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
    • C03C17/28—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material
    • C03C17/30—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D4/00—Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; Coating compositions, based on monomers of macromolecular compounds of groups C09D183/00 - C09D183/16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Definitions

  • the present invention relates to preventive or therapeutic vaccines consisting of viral particles as obtained in vivo after the expression of genes carried by a plasmovirus.
  • a plasmovirus is defined as a plasmid or a viral vector, carrying all the sequences necessary for the reconstitution of a viral particle after expression in a host cell, in vivo , in vitro or ex vivo.
  • the introduction of the plasmovirus into the host cell transforms the latter into a virion-producing packaging cell.
  • Vaccination against viruses and in particular retroviruses is a complex operation. Some strategies have proven to be more or less effective for vaccination against oncoviruses, but trials of vaccines against lentiviruses do not give satisfactory results. One of the reasons which could explain this state of affairs is that all of the phenomena leading to immunization against a virus probably require the existence of physical viral particles and the production of these particles by host cells. Better evidence is that the best vaccination results for monkeys against the SIV virus have been by using attenuated viruses that replicate in vaccinated monkeys. A therapeutic vaccination strategy has been explored by Salk et al, (Proc. Natl. Acad. Sci. USA (1991) 88 : 3348-52) using inactivated HIV particles. This strategy has proven unsatisfactory for two reasons. The first is that it is difficult to produce HIV virus in vitro in sufficient quantity and the second is that the methods of inactivation of said viruses to be effective destroy part of the immunogenic epitopes of the viral particles.
  • the object of the present invention is to have produced by the host cell of viral particles closely reproducing the wild virus particles that are either attenuated or unable to replicate with the host.
  • This vaccination approach consisting in injecting a plasmovirus, the expression of which results in the formation of viral particles, is particularly advantageous in the case where vaccination with viral subunits has not yet succeeded.
  • the idea contained in this approach is that there is no better immunization than that obtained with a physical particle reproducing the infectious particle. This is also why vaccination against many pathogens and viruses in particular, is done using these viruses in attenuated form.
  • all the current trials show that the only way to effectively protect a macaque from an infection by an SIV is the administration of an attenuated strain which effectively protects a challenge against a different and pathogenic virus.
  • the present invention relates to a new means of vaccination based on in vivo administration of one or more plasmids carrying, alone or in combination (s), the structural genes necessary for the constitution of a physical viral particle, either empty or containing a viral genome, defective attenuated or not.
  • the invention resides in particular in the use of plasmoviruses for in vivo production in individuals humans or animals infected or likely to be infected with a virus, of immunogenic viral particles.
  • Attenuated viral genome any viral genome modified in such a way that replication is not very efficient, for example a modification of a gene that would allow infection only by contact and not by dissemination, for example a deletion of the extracellular part of the env gene to keep only the transmembrane, fusogenic part.
  • Any modification of the viral genome likely to confer to the virus this characteristic of attenuation can be qualified by a test infectivity in cell culture where, by conventional techniques, the rate infectious virus present in the culture supernatant is dramatically reduced while cell-to-cell infection is low affected by this change.
  • plasmovirus allowing a reconstitution of viral particles can be implemented in different ways depending on the properties which it is desired to confer on the final pharmaceutical product.
  • plasmovirus Different embodiments of the plasmovirus are conceivable, from the moment when on the same plasmid or vector, or on several plasmids or associated vectors, all of the sequences which after entering DNA or RNA into the cells and being expressed there, reconstitutes a physical viral particle.
  • plasmids or associated vectors By plasmids or associated vectors is meant plasmids, vector or nucleic acid sequences whose expression is substantially simultaneous in cells and are: either unbound or directly or indirectly coupled, covalently or not.
  • the embodiments are then chosen according to the function that we want to give to the virion reconstituted from the construction plasmoviral.
  • the nucleocapsid framework of the virus is that of a retrovirus
  • the embodiments are diverse and may favor either safety, efficiency, or selectivity to a target, or the expression of a particular transgene, i.e. several of these functions simultaneously.
  • the vector may in particular contain the gag gene or the genes gag and env or finally the gag, pol and env genes of the retrovirus, these genes being possibly under the control of independent promoters and / or specific, as well as transgenes of interest under the control of one or the other promoter or an independent promoter.
  • a promoter is said specific or independent if it is different from the promoter of the virus that is reconstituted from the plasmovirus, for example from an LTR.
  • the invention is used for immunization against a retrovirus, such as HIV and involves doing express by host cells retroviral particles carrying the envelope proteins of the virus but lacking the viral genome.
  • a plasmovirus comprising all the sequences necessary for manufacturing, by the host cell, of a virus (gag, pol and env sequence and in particular those HIV1 or / and HIV2) but lacking the sequence ⁇ of encapsidation, the pol gene comprising, where appropriate, mutations in INT and // or in RT. which leads to reconstitution in the target cell of an empty particle or carrier of a defective genome.
  • a plasmovirus is used containing the sequences gag, pol and provided with a mutated env gene or deficient.
  • Another embodiment is that in which the plasmovirus is provided with the packaging sequence but devoid of certain genes especially those of reverse transcriptase and / or integrase removing the latter any ability to replicate and / or propagate in the organism.
  • the gene can be inserted either under the control of the gag / pol promoters or under the control of the env promoter. If its expression is under the control of a retrovirus LTR, and the nucleocapsid framework contains the sequence ⁇ , this gene will be reintegrated into the virions formed after transfection of the target cells, and its expression may be continued after the formation of the virion in situ .
  • the physical particle reconstituted in vivo which acts as a vaccine eliciting a cellular and humoral response.
  • This approach is particularly interesting in the case of the search for a protective vaccine against a virus for which no vaccine has been developed.
  • This is particularly the case for HIV and HTLV, spumaviruses or type D retroviruses, for which all attempts to develop vaccines have proved insufficient as regards their protective effect (Medicine / Science, 1996 n ° 1 volume 12 , pages 87-93).
  • the vaccine is particularly advantageous when the viral genome of the plasmovirus is that of a retrovirus, and the coding vector contains at least one gene of HIV structure.
  • the properties of plasmoviruses, and therefore uses of the invention also result from the type of envelope used.
  • the envelope protein is involved not only in the effectiveness of production of infectious mature particles but also allows give this particle a specificity of infection (tropism) because it is this protein which intervenes in the phenomena of binding of the virion to the cell through membrane receptors, and it's involved in the fusion of viral and plasma membranes, which allows release of the nucleocapsid into the cytoplasm of infected cells.
  • the envelope plays an important role in the resistance of the vector to inactivation by complement. That way, on a frame nucleocapsid, the vector's infection spectrum can be changed to modifying the envelope gene, thus allowing it to be adapted to the the vaccination strategy that we wish to adopt.
  • VSV vesicular stomatal virus
  • a protein of the herpes simplex virus type 1 (HSV-1) called Us11 is capable of activating in trans expression of the envelope glycoprotein of the retrovirus and in particular of HIV. or HTLV (J. Diaz et al. (1996), Nature 379 : 273).
  • the inclusion of the gene encoding Us11 in the plasmovirus either under the dependence of the promoter of the retrovirus, or under the dependence of another promoter, for example the promoter pCMV used for the transcription of a structural gene of the retrovirus is particularly advantageous. .
  • the target cells that we wish to target can be determined.
  • each of the required proteins can be placed in a independent expression cassette.
  • several cassettes can follow one another (gag / pol, env, tat, rev, nave).
  • This construction is close to that of plasmoviruses already described in the prior art allows expression by the cell transduced by a foreign gene which can be for example a gene encoding for an immunostimulatory protein. Also in a ⁇ + version of this construction, infectious but defective particles are produced. So cells can become infected and express again proteins necessary for the formation of viral particles. If these cells are antigen presenting cells, this can be particularly advantageous.
  • FIG. 3 Another example of a plasmovirus is shown in the Figure 3 and includes an attenuated viral genome lacking the séquence sequence and of which several modifications are introduced into the genome to avoid the appearance of replicating viruses.
  • the 3 'LTR is replaced by a different polyadenylation; mutations (point mutations, deletions, change of phase of readings ...) are carried out in one or more non-structural proteins (RT reverse transcriptase, IN integrase).
  • RT reverse transcriptase RT reverse transcriptase, IN integrase
  • the present invention also relates to the use of one or more several plasmoviruses as defined above for the manufacture of a immunogenic composition, especially a vaccine, for prophylaxis and / or the therapy of individuals infected or likely to be infected with a virus, by administration of said plasmovirus (s) in vivo.
  • immunogenic compositions or vaccines may be medical human or veterinary.
  • composition is more particularly immunogenic in the sense that the injection of the vector carrying the defective viral genome allows the reconstitution of a physical particle likely to elicit a cellular and / or humoral immune response.
  • the defective viral genome and the sequences encoding the or the gene (s) allowing the reconstitution of the viral envelope can be carried by one or two vectors, which are associated in the composition, these can be linked by means known to those skilled in the art, in particular those described in patent application WO 95/26411.
  • the term plasmovirus applies equally to a single vector carrying both the specific sequences of the defective viral genome, and the sequences encoding the structural protein (s) as well as the where appropriate, the sequences coding for the exogenous genes mentioned above, either to increase immunogenicity or to increase system security, or finally to allow better expression proteins from the viral envelope.
  • a vaccination adjuvant can be used to prepare the immunogenic composition, associated with the plasmovirus.
  • Adjuvants can be of several types; some promote the classic immune response as an N-acetyl-muramyl adjuvant associated with a peptide such as MDP or its various derivatives such as those described in. CRS Critical Reviews in immunology, 1988, Vol. 8, pages 83-100. Other types of adjuvant can be envisaged, such as those which promote the penetration of nucleic acid sequences into cells; finally, the plasmovirus in the immunogenic composition can be linked to a sequence known as or presumed to be T-dependent or alternatively linked or encompassed in liposomes.
  • aqueous or oily media in the form of subcutaneous, intramuscular or intravenous injections by "pellets” (biodegradable polymers containing the product) and / or by implantation of the release system by micropump.
  • Other adjuvants such as PAO, alone or combined with lecithin (EP445-710) ZN (OH) or HBW538 (Drugs experimental clinical research (1991) 17 (9): 445450) associated with aluminum hydroxide (Al (OH) 3) may or may not be covalently associated with the active ingredient for the composition.
  • the immunogenic composition one of the active principles of which is the plasmovirus, is also characterized in that the defective viral genome carries a suicide gene in order to allow system security by the addition, if necessary, of ganciclovir when it is desired to stop the proliferation of said virus.
  • the plasmovirus can be either naked or coated DNA or naked DNA associated with a packaging cell type cell or a cell established in line which can be chosen for example from among fibroblastic lines such as the 3T3 line or susceptible lines to be grown in suspension like myeloma cells, cells Vero or MRC5 cells.
  • the immunogenic composition is the whole of the plasmovirus and the host cell which acts, in this case, like a cell transplant to produce the viral particle which, itself, will elicit the vaccine reaction.
  • 0.1 to 1000 ⁇ g of acids are used for immunization nucleic acid constituting the vector per dose and preferably from 10 to 500 ⁇ g per dose. These doses are understood as unit dose intended for humans.
  • the plasmovirus can also be a virus such as adenovirus or AAV (adeno-associated virus) defective and carrying all the sequences necessary for the reconstruction a retrovirion; in other words, the defective virus, carrying the sequences retroviral acts as a transporter for cells that need to be preferentially targeted.
  • viruses such as adenovirus or AAV (adeno-associated virus) defective and carrying all the sequences necessary for the reconstruction a retrovirion; in other words, the defective virus, carrying the sequences retroviral acts as a transporter for cells that need to be preferentially targeted.
  • the AAV has a particular tropism for muscle cells that have a strong immunogenic capacity; the introduction of the genome carrying retroviral sequences in this type of cell may increase the vaccinating effect.
  • 100 to 106 are used defective viral particles per unit dose intended preferably for humans.
  • composition according to the invention can be intended for the implementation of an active immunization method individuals against viral infection, said method comprising injecting an individual a plasmovirus carrying the structural genes necessary for the reconstitution of a viral particle.
  • the injected plasmovirus can also carry a viral genome or retroviral, preferably defective and carrying non-coding sequences and / or regulators of the virus or retrovirus, and where appropriate of a packaging sequence.
  • the retroviral genomes that are preferred in as part of a vaccination method are those of lentiviruses, oncomavirus, spumavirus or type D retrovirus.
  • the structural genes necessary for the constitution of the virus particles are preferably the genes coding for gag and / or env. The gene approx. is chosen according to the purpose assigned to the plasmovirus, different examples being cited above.
  • the env gene can be recombined in such a way way that a chimera is produced, which carries both the function attachment to the target cell receptor of the virion and the receptor for the insert in the molecule approx.
  • it can be also advantageous to add to the plasmovirus the Us11 gene of HSV1 so as to stimulate the synthesis of structural proteins.
  • the retroviral genome lacks the sequence encapsidation, the reconstituted physical particles are then lacking a genome.
  • the viral genome carries this packaging sequence, it may be interesting to construct the vector in such a way that depending on the retroviral promoter, a gene of interest either added to increase system security or increase the immune response of the vaccine.
  • This immunization can be obtained after percutaneous injection or subcutaneous, intramuscular or intravenous immunogenic composition as described above.
  • plasmoviruses according to the invention is advantageous insofar as the preparation and storage of nucleic acids is easier to implement than the production and conservation of complete virus particles.
  • FIG. 4 represents the plasmid pBMC-3 comprising an HSV1-TK gene under the control of a 5 'Mo-MuLV LTR promoter.
  • FIG. 5 represents the plasmid pNP-2.
  • Figure 6 shows the variation in weight of the animals vaccinated with these constructs and infected with the leukemia virus murine myeloproliferative. On the abscissa are indicated the examination days and on the ordinate the variations in the weights of the animals.
  • the experimental model used is the induction of leukemia megakaryocytic in mice.
  • This leukemia is induced by infection of the mouse with a pathogenic MPLV retrovirus.
  • the MPLV virus is derived from friend-like murine leukemia viruses.
  • the latter have LTR sequences distinct from moloney-like viruses but have extremely similar structural protein sequences. It is therefore possible to vaccinate against MPLV using protein derived moloney viruses.
  • Such a virus carries a v-mpl oncogene, which is the ligand for thrompoietin. After infection with such a virus, the mouse develops a few weeks megakaryotic leukemia. This disease is characterized by spleno-megaly and hepatomegaly; more specifically, after viral infection, an extremely large number of lymphocytes accumulate in the spleen. Also a vaccinating effect can be appreciated by the absence of an increase in the weight of the spleen, liver or of the whole animal after a challenge with pathogenic virus.
  • Plasmoviruses used in this model are identical to Plasmoviruses used in this model:
  • mice are injected intramuscularly as described by Ulmer et al, Science, 1993 259 : 1745-1749.
  • mice are injected with plasmid DNA completely foreign to the MPLV virus.
  • the animals are injected intravenously with a culture supernatant from a line cell producing MPLV virus.
  • This undiluted supernatant has a reverse transcriptase (RT) activity of 66152 CPM / 10 6 cells.
  • RT reverse transcriptase
  • FIG. 6 represents the variation in the weight of the animal at different times after the challenge by MPLV particles.
  • the circles blanks represent the results after vaccination with the plasmid pBMC-3.
  • the black circle represents the results obtained after vaccination with pNP-2.
  • the white square represents the results obtained with pBXT4, plasmid providing the cDNA of human CD4, and the squares black represent the control in which the mice were not vaccinated prior to the injection of the viral particles.
  • the table below indicates the weight of the spleen and the liver respectively after sampling, 21 days after the injection of the viral particles.
  • Type of vaccination Increase in the weight of the spleen on the 21st day Increase in liver weight on the 21st day pBMC-3 x 1 x 0.8 pNP-2 x 16.3 x 1.3 hCD4 x 12.5 x 1.3 no vaccine x 11.0 x 1.1

Claims (18)

  1. Verwendung eines oder mehrerer Plasmide, die, einzeln oder in Kombination, die Sequenzen von viralen Strukturgenen umfassen, die nach Expression in einer Zelle zur Neubildung eines viralen Partikels, das leer ist oder ein für die Replikation defektes Genom enthält, notwendig sind, zur Herstellung einer Zusammensetzung, die zur Verwendung in einem Impfverfahren beim Menschen oder Tier durch Verabreichen des oder besagter Plasmide an einen Menschen oder an ein Tier bestimmt ist.
  2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass die besagten Sequenzen in dem oder den Plasmiden unter Kontrolle unabhängiger und/oder spezifischer Promotoren oder einer LTR stehen.
  3. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass das virale Partikel ein retrovirales Partikel ist.
  4. Verwendung nach Anspruch 3, dadurch gekennzeichnet, dass das retrovirale Partikel ein HIV, ein HTLV, ein Spumavirus oder ein Typ D Retrovirus ist.
  5. Verwendung eines Plasmids nach einem der vorausgehenden Ansprüche, das eine Sequenz umfasst, die ein gag Protein eines Retrovirus codiert.
  6. Verwendung eines Plasmids nach einem der Ansprüche 1 bis 4, das eine Sequenz, die ein gag Protein codiert, und eine Sequenz eines Retrovirus umfasst, die ein env Protein codiert.
  7. Verwendung eines Plasmids nach einem der Ansprüche 1 bis 4, das eine Sequenz, die ein gag Protein codiert, eine Sequenz, die ein pol Protein codiert, und eine Sequenz eines Retrovirus umfasst, die ein env Protein codiert.
  8. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass die zur Neubildung des viralen Partikels notwendigen Sequenzen ohne Verpackungssequenz sind.
  9. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass die zur Neubildung des viralen Partikels notwendigen Sequenzen ohne invertierte terminale Wiederholungssequenzen (LTR) des Virus sind.
  10. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass das oder die Plasmide außerdem eine Nucleinsäure umfassen, die ein Peptid, Polypeptid oder Protein codiert, gegen das eine Immunisierung erstrebt ist.
  11. Verwendung nach Anspruch 6, 7 oder 10, dadurch gekennzeichnet, dass das besagte Peptid, Polypeptid oder Protein an das besagte env Protein fusioniert ist und dass das besagte Peptid, Polypeptid oder Protein an der Oberfläche des neugebildeten viralen Partikels exprimiert wird.
  12. Verwendung nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, dass das oder die Plasmide außerdem eine Nucleinsäure umfassen, die einen Immunmodulator, vorzugsweise ein Cytokin oder ein Protein des Haupthistokompatibilitätskomplexes, codiert.
  13. Verwendung nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, dass das oder die Plasmide außerdem eine Nucleinsäure umfassen, die ein bedingtes Toxin codiert.
  14. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass das oder die Plasmide außerdem eine Nucleinsäure umfassen, die das Protein Us11 von HSV-1 codiert.
  15. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass das oder die Plasmide intramuskulär verabreicht werden.
  16. Verwendung nach einem der Ansprüche 1 bis 14, dadurch gekennzeichnet, dass das oder die Plasmide intravenös oder subkutan verabreicht werden.
  17. Verwendung nach einem der vorausgehenden Ansprüche, dadurch gekennzeichnet, dass die gesamten zur Neubildung des viralen Partikels notwendigen Sequenzen von einem einzigen Plasmid umfasst sind.
  18. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass das virale Partikel ein retrovirales Partikel ist und dass das, die oder mehrere Plasmide durch einen Adenovirus-Vektor oder AAV ersetzt sind.
EP97400796A 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier Expired - Lifetime EP0799893B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01102630A EP1138773A2 (de) 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9604370 1996-04-05
FR9604370A FR2747046B1 (fr) 1996-04-05 1996-04-05 Nouveaux vaccins issus de plasmovirus
US09/166,147 US6140114A (en) 1996-04-05 1998-10-05 Defective viral vaccine particles obtained in vivo or ex vivo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01102630A Division EP1138773A2 (de) 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier

Publications (2)

Publication Number Publication Date
EP0799893A1 EP0799893A1 (de) 1997-10-08
EP0799893B1 true EP0799893B1 (de) 2001-09-12

Family

ID=26232637

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97400796A Expired - Lifetime EP0799893B1 (de) 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
EP01102630A Withdrawn EP1138773A2 (de) 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01102630A Withdrawn EP1138773A2 (de) 1996-04-05 1997-04-07 Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier

Country Status (10)

Country Link
US (1) US6140114A (de)
EP (2) EP0799893B1 (de)
JP (1) JP2000508893A (de)
AT (1) ATE205537T1 (de)
AU (1) AU2394297A (de)
CA (1) CA2251027C (de)
DE (1) DE69706593T2 (de)
ES (1) ES2164309T3 (de)
FR (1) FR2747046B1 (de)
WO (1) WO1997038118A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391542C (zh) * 1997-09-15 2008-06-04 遗传免疫有限公司 向抗原呈递细胞递送基因的药物组合物及其用途
AU1087299A (en) * 1997-10-14 1999-05-03 Avant Immunotherapeutics, Inc. Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
JP2003535565A (ja) * 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
WO2002030471A2 (en) * 2000-10-10 2002-04-18 Institut für Virologie Teilrechtsfähiges Institut an der Veterinärmedizinischen Universität Wien A novel system for the evaluation of the activity and/or specificity of a viral component
EP1201750A1 (de) 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
AU2002255532A1 (en) * 2001-02-13 2002-10-15 Joseph D. Mosca Biological carriers for induction of immune responses
ES2334335T3 (es) * 2001-03-08 2010-03-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Mva que expresa genes de envoltura, gag y pol de vih modificados.
JP2007505130A (ja) * 2003-09-09 2007-03-08 バイレクシス コーポレイション ヒトにおいてｈｉｖに対する免疫応答を生成するための、レンチウイルスベクターベースのアプローチ
CN100549021C (zh) 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
JP2008502905A (ja) * 2004-06-15 2008-01-31 セントカー・インコーポレーテツド ヒト前立腺疾患に対する作用物質のスクリーニング法
EP1786445B1 (de) * 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Lebendige mikrobielle mikrobizide
EP1885186B1 (de) * 2005-06-01 2015-09-02 California Institute Of Technology Verfahren zur gezielten genabgabe über virale vektoren
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
JP5539718B2 (ja) 2006-07-21 2014-07-02 カリフォルニア インスティテュート オブ テクノロジー 樹状細胞の免疫付与用の、標的特異的な遺伝子輸送
US20090169519A1 (en) * 2007-02-21 2009-07-02 Rajesh Shah Medicinal formulation containing a combination of hiv type i and hiv type ii
CN102482329B (zh) 2009-07-24 2017-11-14 免疫设计公司 用辛德毕斯病毒包膜糖蛋白假型化的慢病毒载体
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EP3480316B1 (de) 2012-03-30 2022-09-14 Immune Design Corp. Lentivirale vektorpartikel mit verbesserter transduktionseffizienz for dc-sign exprimierende zellen
WO2017223146A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3697806A4 (de) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberkulose-antigen-kassetten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001032A3 (de) * 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
DK0630409T3 (da) * 1992-02-28 2003-03-24 Syngenix Ltd Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV
CA2117884A1 (en) * 1992-03-27 1993-10-14 Anna Aldovini Non-infectious hiv particles and uses therefor
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Res Found Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) * 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
CZ259197A3 (cs) * 1995-02-24 1998-01-14 Clipmate Corporation Rozbušková sestava, balení rozbuškových sestav a způsob sestavování rozbušky a zesilovací nálože

Also Published As

Publication number Publication date
CA2251027C (fr) 2009-11-10
CA2251027A1 (fr) 1997-10-16
AU2394297A (en) 1997-10-29
EP1138773A2 (de) 2001-10-04
WO1997038118A1 (fr) 1997-10-16
JP2000508893A (ja) 2000-07-18
US6140114A (en) 2000-10-31
FR2747046B1 (fr) 1998-06-19
EP0799893A1 (de) 1997-10-08
FR2747046A1 (fr) 1997-10-10
ES2164309T3 (es) 2002-02-16
DE69706593D1 (de) 2001-10-18
DE69706593T2 (de) 2002-07-11
ATE205537T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
EP0799893B1 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
CA2183151C (fr) Systeme hote-vecteur utilisable en therapie genique
EP1761635B1 (de) Nicht integrativer und nicht replikativer lentivirus, herstellung und verwendungen
JPH08509606A (ja) 細胞内感染因子に感染した個体を処置する方法および物質
US20220106385A1 (en) Use of modified hiv-1 for generating fully human antibodies
WO1998026074A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
Kaulfuß et al. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery
Schultz et al. The HIV vaccine pipeline, from preclinical to phase III
CA3078717A1 (fr) Particules pseudo-virales utiles pour traiter des maladies auto-immunes
EP2020444B1 (de) Defekte nicht-integrative lentivirale Transfervektoren für Impfstoffe
EP0354109B1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
Hu et al. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity
CA2448947C (fr) Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus
WO2002088339A2 (fr) Particules pseudovirales de birnavirus
EP0420759A1 (de) Verfahren zur Herstellung einer immunwirksamen Zusammensetzung
WO2004110485A1 (en) Materials and methods for improved vaccination
JP2024509976A (ja) 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
WO2022191801A2 (en) Integrase defective hiv-based lentivirus mediated new generation covid-19 vaccine encoding sars-cov-2 spike protein
Jia et al. Single-cycle SIV: a novel AIDS vaccine approach
Lipopolymer Infectious Diseases and Vaccines
Smith et al. Retroviral and lentiviral gene therapy for autoimmune disease
Strayer et al. Virus-based vectors for gene expression in mammalian cells: SV40
Ward Novel fusion protein-expressing lentiviral vectors ameliorate collagen induced arthritis
FR2652504A1 (fr) Composition immunisante et procede de preparation.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990325

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: USE OF PLASMIDS FOR THE MANUFACTURE OF A COMPOSITION FOR VACCINE TREATMENT BY HUMAN AND ANIMAL

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010912

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010912

REF Corresponds to:

Ref document number: 205537

Country of ref document: AT

Date of ref document: 20010915

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20010912

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: FRENCH

REF Corresponds to:

Ref document number: 69706593

Country of ref document: DE

Date of ref document: 20011018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011212

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011212

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20011214

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2164309

Country of ref document: ES

Kind code of ref document: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020407

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020407

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020430

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160404

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160419

Year of fee payment: 20

Ref country code: GB

Payment date: 20160421

Year of fee payment: 20

Ref country code: ES

Payment date: 20160518

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160422

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69706593

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20170406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170406

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170408